Free Trial

Elevance Health (ELV) Financials

Elevance Health logo
$392.74 +0.06 (+0.01%)
Closing price 05/15/2026 03:59 PM Eastern
Extended Trading
$387.42 -5.31 (-1.35%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Elevance Health

Annual Income Statements for Elevance Health

This table shows Elevance Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
2,560 2,470 3,843 3,750 4,807 4,572 6,158 5,894 5,987 5,980 5,662
Consolidated Net Income / (Loss)
2,560 2,470 3,843 3,750 4,807 4,572 6,149 5,888 5,991 5,971 5,661
Net Income / (Loss) Continuing Operations
2,560 2,470 3,843 3,750 4,807 4,572 6,149 5,888 5,991 5,971 5,661
Total Pre-Tax Income
4,631 4,555 3,964 5,068 5,985 6,238 7,995 7,600 7,715 7,904 6,710
Total Operating Income
5,275 5,278 4,985 5,832 6,733 7,058 8,793 8,451 8,745 8,888 8,112
Total Gross Profit
18,040 18,029 17,804 20,210 20,435 24,869 25,173 26,918 29,717 9,468 29,724
Total Revenue
79,157 84,863 90,040 92,105 104,213 121,867 138,639 156,595 171,340 176,810 199,125
Operating Revenue
79,157 84,863 90,040 86,185 104,213 115,552 138,639 156,595 171,340 177,255 199,125
Total Cost of Revenue
61,117 66,834 72,236 71,895 83,778 96,998 113,466 129,677 141,623 167,342 169,401
Operating Cost of Revenue
61,117 66,834 72,236 71,895 83,778 96,998 113,466 129,677 141,623 167,342 169,401
Total Operating Expenses
12,765 12,751 12,819 14,378 13,702 17,811 16,380 18,467 20,972 580 21,612
Selling, General & Admin Expense
12,535 12,559 12,650 14,020 13,364 17,450 15,918 17,700 20,087 - 20,984
Amortization Expense
230 192 169 358 338 361 441 767 885 580 628
Total Other Income / (Expense), net
-644 -723 -1,021 -764 -748 -820 -798 -851 -1,030 -984 -1,402
Interest Expense
644 723 1,021 764 748 820 798 851 1,030 1,185 1,402
Other Income / (Expense), net
- - - - - - - 0.00 0.00 201 0.00
Income Tax Expense
2,071 2,085 121 1,318 1,178 1,666 1,846 1,712 1,724 1,933 1,049
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - 0.00 0.00 -9.00 -6.00 4.00 -9.00 -1.00
Basic Earnings per Share
$9.73 $9.39 $14.70 $14.53 $18.81 $18.23 $25.26 $24.56 $25.38 $25.81 $25.28
Weighted Average Basic Shares Outstanding
263M 262.90M 261.50M 258.10M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Diluted Earnings per Share
$9.38 $9.21 $14.35 $14.19 $18.47 $17.98 $24.95 $24.28 $25.22 $25.68 $25.21
Weighted Average Diluted Shares Outstanding
263M 262.90M 261.50M 258.10M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Weighted Average Basic & Diluted Shares Outstanding
263M 262.90M 261.50M 258.10M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Cash Dividends to Common per Share
$2.50 $2.60 $2.70 $3.00 $3.20 $3.80 $4.52 $5.12 $5.92 $6.52 $6.84

Quarterly Income Statements for Elevance Health

This table shows Elevance Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
1,289 856 2,246 2,300 1,016 418 2,183 1,743 1,189 547 1,764
Consolidated Net Income / (Loss)
1,300 831 2,249 2,301 1,008 413 2,184 1,744 1,187 546 1,760
Net Income / (Loss) Continuing Operations
1,300 831 2,249 2,301 1,008 413 2,184 1,744 1,187 546 1,760
Total Pre-Tax Income
1,654 1,001 2,939 2,986 1,373 606 2,797 2,292 1,406 215 2,304
Total Operating Income
1,913 1,260 3,204 3,026 1,712 946 3,141 2,633 1,757 581 2,661
Total Gross Profit
7,595 11,294 8,206 8,254 1,834 16,265 8,596 7,777 7,191 6,160 9,103
Total Revenue
42,849 42,647 42,577 43,646 45,145 45,442 48,891 49,776 50,711 49,747 50,181
Operating Revenue
42,849 42,413 42,577 43,646 45,270 45,516 48,891 49,776 50,711 49,747 50,181
Total Cost of Revenue
35,254 31,353 34,371 35,392 43,311 29,177 40,295 41,999 43,520 43,587 41,078
Operating Cost of Revenue
35,254 31,353 34,371 35,392 43,311 29,177 40,295 41,999 43,520 43,587 41,078
Total Operating Expenses
5,682 10,034 5,002 5,228 122 15,319 5,455 5,144 5,434 5,579 6,442
Selling, General & Admin Expense
5,470 - 4,886 5,066 - - 5,300 4,997 5,272 5,415 6,330
Amortization Expense
212 217 116 162 122 180 155 147 162 164 112
Total Other Income / (Expense), net
-259 -259 -265 -40 -339 -340 -344 -341 -351 -366 -357
Interest Expense
259 259 265 280 300 340 344 341 351 366 357
Other Income / (Expense), net
0.00 - - 240 -39 - 0.00 0.00 0.00 - 0.00
Income Tax Expense
354 170 690 685 365 193 613 548 219 -331 544
Net Income / (Loss) Attributable to Noncontrolling Interest
11 -25 3.00 1.00 -8.00 -5.00 1.00 1.00 -2.00 -1.00 -4.00
Basic Earnings per Share
$5.48 $3.70 $9.65 $9.91 $4.38 $1.87 $9.64 $7.74 $5.32 $2.58 $8.03
Weighted Average Basic Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Diluted Earnings per Share
$5.45 $3.68 $9.59 $9.85 $4.36 $1.88 $9.61 $7.72 $5.32 $2.56 $8.00
Weighted Average Diluted Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Weighted Average Basic & Diluted Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Cash Dividends to Common per Share
$1.48 - $1.63 $1.63 $1.63 - $1.71 $1.71 $1.71 - $1.72

Annual Cash Flow Statements for Elevance Health

This table details how cash moves in and out of Elevance Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-38 1,962 -466 325 1,003 804 -861 2,507 -861 1,828 1,203
Net Cash From Operating Activities
4,212 3,270 4,185 3,827 6,061 10,688 8,364 8,399 8,061 5,808 4,290
Net Cash From Continuing Operating Activities
4,212 3,270 4,185 3,827 6,128 10,688 8,364 8,399 8,061 5,808 4,290
Net Income / (Loss) Continuing Operations
2,560 2,470 3,843 3,750 4,807 4,572 6,149 5,888 5,991 5,971 5,661
Consolidated Net Income / (Loss)
2,560 2,470 3,843 3,750 4,807 4,572 6,149 5,888 5,991 5,971 5,661
Depreciation Expense
106 104 111 1,132 1,133 1,154 1,302 1,675 1,745 1,393 1,546
Non-Cash Adjustments To Reconcile Net Income
21 97 235 432 201 248 -552 528 1,462 537 639
Changes in Operating Assets and Liabilities, net
723 -209 -784 -1,487 -13 4,714 1,465 308 -1,137 -2,093 -3,556
Net Cash From Investing Activities
-1,152 -514 -5,082 -1,259 -2,792 -7,324 -9,638 -4,560 -5,572 -5,167 -1,344
Net Cash From Continuing Investing Activities
-1,152 -514 -5,082 -1,259 -2,792 -7,324 -9,638 -4,560 -5,572 -5,167 -1,344
Purchase of Property, Plant & Equipment
-638 -584 -791 -1,208 -1,077 -1,021 -1,087 -1,152 -1,296 -1,256 -1,116
Acquisitions
-639 0.00 -2,080 -1,760 0.00 -1,976 -3,476 -649 -1,552 -4,809 88
Purchase of Investments
-11,681 -11,845 -16,375 -9,820 -22,700 -20,341 -19,625 -25,247 -16,158 -17,913 -15,411
Divestitures
- - - - - - - 0.00 0.00 363 0.00
Sale and/or Maturity of Investments
11,780 11,918 14,152 11,600 21,035 16,059 14,613 22,608 13,536 18,572 15,095
Other Investing Activities, net
-8.20 -3.00 12 -71 -50 -45 -63 -120 -102 -124 0.00
Net Cash From Financing Activities
-3,093 -799 427 -2,241 -2,266 -2,567 423 -1,318 -3,349 1,193 -1,738
Net Cash From Continuing Financing Activities
-3,093 -799 427 -2,241 -2,266 -2,567 423 -1,318 -3,349 1,193 -1,738
Repayment of Debt
-4,635 -2,553 -7,815 -11,227 -9,455 -3,750 -2,091 -3,533 -2,167 -1,783 -3,845
Repurchase of Common Equity
-1,516 0.00 -1,998 -1,685 -1,701 -2,700 -1,900 -2,316 -2,676 -2,900 -2,605
Payment of Dividends
-657 -684 -705 -776 -818 -954 -1,104 -1,229 -1,395 -1,508 -1,529
Issuance of Debt
3,987 2,400 11,468 9,955 9,859 3,454 4,837 4,436 2,799 7,985 4,496
Issuance of Common Equity
- 0.00 0.00 1,250 - - - 182 152 221 79
Other Financing Activities, net
-272 38 -523 242 -151 1,383 681 1,142 -62 -822 1,666
Effect of Exchange Rate Changes
-5.30 5.00 4.00 -2.00 0.00 7.00 -10 -14 -1.00 -6.00 -5.00

Quarterly Cash Flow Statements for Elevance Health

This table details how cash moves in and out of Elevance Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
928 -4,393 -300 292 1,368 468 -788 1,060 153 778 166
Net Cash From Operating Activities
2,613 -2,971 1,978 447 2,677 706 1,017 2,054 1,135 84 4,332
Net Cash From Continuing Operating Activities
2,613 -2,971 1,978 447 2,677 706 1,017 2,054 1,135 84 4,332
Net Income / (Loss) Continuing Operations
1,300 831 2,249 2,301 1,008 413 2,184 1,744 1,187 546 1,760
Consolidated Net Income / (Loss)
1,300 831 2,249 2,301 1,008 413 2,184 1,744 1,187 546 1,760
Depreciation Expense
426 424 331 335 329 398 373 380 387 406 354
Non-Cash Adjustments To Reconcile Net Income
645 371 250 -64 322 29 419 200 42 -22 -168
Changes in Operating Assets and Liabilities, net
242 -4,597 -852 -2,125 1,018 -134 -1,959 -270 -481 -846 2,386
Net Cash From Investing Activities
-687 -1,029 -2,310 -818 -401 -1,638 103 -687 -1,224 464 -1,642
Net Cash From Continuing Investing Activities
-687 -1,029 -2,310 -818 -401 -1,638 103 -687 -1,224 464 -1,642
Purchase of Property, Plant & Equipment
-319 -326 -279 -323 -332 -322 -196 -267 -360 -293 -235
Acquisitions
81 18 -1,120 -4.00 - -3,685 4.00 50 1.00 33 5.00
Purchase of Investments
-6,779 8,124 -6,315 -4,041 -4,510 -3,047 -4,254 -4,314 -4,273 -2,570 -5,048
Divestitures
- - - - - -36 0.00 - - - 0.00
Sale and/or Maturity of Investments
6,366 -8,825 5,433 3,187 4,472 5,480 4,574 3,857 3,422 3,242 3,646
Other Investing Activities, net
-36 -20 -29 -36 -31 -28 -25 -13 -14 52 -10
Net Cash From Financing Activities
-994 -394 32 668 -915 1,408 -1,909 -308 243 236 -2,515
Net Cash From Continuing Financing Activities
-994 -394 32 668 -915 1,408 -1,909 -308 243 236 -2,515
Repayment of Debt
-265 1.00 4.00 4.00 -874 -917 -1,379 113 -2,049 -530 -903
Repurchase of Common Equity
-480 -928 -566 -463 -60 -1,811 -880 -378 -876 -471 -1,124
Payment of Dividends
-348 -346 -379 -378 -378 -373 -386 -385 -381 -377 -376
Issuance of Debt
- 225 1,350 1,230 210 5,195 0.00 - 3,984 512 724
Other Financing Activities, net
99 502 -377 275 187 -907 736 342 -435 1,023 -836
Effect of Exchange Rate Changes
-4.00 1.00 0.00 -5.00 7.00 -8.00 1.00 1.00 -1.00 -6.00 -9.00

Annual Balance Sheets for Elevance Health

This table presents Elevance Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
61,718 65,083 70,540 71,571 77,453 86,615 97,456 102,755 108,928 116,889 121,494
Total Current Assets
30,862 34,315 36,263 34,321 39,033 45,751 51,122 55,617 60,029 58,942 63,001
Cash & Equivalents
2,114 4,075 3,609 3,934 4,937 5,741 4,880 7,387 6,526 8,288 9,491
Short-Term Investments
18,552 18,812 21,156 18,368 20,685 24,992 28,148 26,905 29,843 26,393 26,624
Accounts Receivable
7,024 8,397 4,847 4,836 5,377 5,679 7,759 8,961 9,963 11,060 11,469
Other Current Assets
2,856 2,862 6,309 7,173 8,034 9,339 10,335 12,364 13,697 13,201 15,417
Plant, Property, & Equipment, net
2,020 1,978 2,175 2,735 3,133 3,483 3,919 4,316 4,359 4,652 4,679
Total Noncurrent Assets
28,836 28,790 32,102 34,515 35,287 37,381 42,415 42,822 44,540 53,295 53,814
Long-Term Investments
2,630 2,796 3,905 4,213 4,763 4,847 5,857 6,437 6,983 10,784 11,960
Goodwill
17,562 17,561 19,231 20,504 20,500 21,691 24,228 24,383 25,317 28,277 28,344
Intangible Assets
8,158 7,965 8,368 9,007 8,674 9,405 10,615 10,315 10,273 12,094 11,200
Other Noncurrent Operating Assets
485 468 598 791 1,350 1,438 1,715 1,687 1,967 2,140 2,310
Total Liabilities & Shareholders' Equity
61,718 65,083 70,540 71,571 77,453 86,615 97,456 102,755 108,928 116,889 121,494
Total Liabilities
38,674 39,983 44,037 43,030 45,725 53,416 61,293 66,425 69,523 75,463 77,468
Total Current Liabilities
19,093 21,294 23,356 21,965 23,532 29,453 34,885 39,696 41,791 40,581 41,035
Short-Term Debt
540 1,368 2,550 1,994 2,298 700 1,874 1,765 1,874 2,014 1,249
Accounts Payable
10,889 11,908 13,016 12,413 4,198 16,852 4,970 5,607 6,910 6,927 7,322
Other Current Liabilities
6,291 6,868 7,266 6,879 17,036 11,901 28,041 32,324 33,007 31,487 32,464
Total Noncurrent Liabilities
19,581 18,688 20,681 21,065 22,193 23,963 26,408 26,729 27,732 34,882 36,433
Long-Term Debt
15,325 14,359 17,382 17,217 17,787 19,335 21,157 22,349 23,246 29,218 30,797
Noncurrent Deferred & Payable Income Tax Liabilities
2,631 2,780 1,727 1,960 2,227 2,019 2,815 2,015 1,970 2,148 2,110
Other Noncurrent Operating Liabilities
1,626 1,550 1,572 1,888 2,179 2,609 2,436 2,365 2,516 3,516 3,526
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
23,044 25,100 26,503 28,541 31,728 33,199 36,163 36,330 39,405 41,426 44,026
Total Preferred & Common Equity
23,044 25,100 26,503 28,541 31,728 33,199 36,095 36,243 39,306 41,315 43,882
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
23,044 25,100 26,503 28,541 31,728 33,199 36,095 36,243 39,306 41,315 43,882
Common Stock
8,558 8,808 8,550 9,539 9,451 9,247 9,150 9,086 8,870 8,913 8,940
Retained Earnings
14,779 16,561 18,054 19,988 22,573 23,802 27,142 29,647 31,749 33,549 35,393
Accumulated Other Comprehensive Income / (Loss)
-293 -268 -101 -986 -296 150 -197 -2,490 -1,313 -1,147 -451
Other Equity Adjustments
- - - - - - 0.00 - - - 0.00
Noncontrolling Interest
- - - - - 0.00 68 87 99 111 144

Quarterly Balance Sheets for Elevance Health

This table presents Elevance Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
109,168 110,478 108,928 111,894 112,988 116,533 116,889 119,717 121,938 122,749 125,827
Total Current Assets
59,743 61,185 60,029 60,948 62,274 62,846 58,942 61,121 63,324 63,778 67,032
Cash & Equivalents
9,991 10,919 6,526 6,226 6,497 7,866 8,288 7,500 8,560 8,713 9,657
Short-Term Investments
28,293 27,976 29,843 30,041 29,494 30,067 26,393 26,152 26,232 27,503 27,416
Accounts Receivable
9,092 9,049 9,963 9,362 11,178 11,190 11,060 11,822 12,660 12,814 11,265
Other Current Assets
12,367 13,241 13,697 15,319 15,105 13,723 13,201 15,647 15,872 14,748 18,694
Plant, Property, & Equipment, net
4,547 4,248 4,359 4,451 4,450 4,505 4,652 4,617 4,641 4,657 4,657
Total Noncurrent Assets
44,878 45,045 44,540 46,495 46,264 49,182 53,295 53,979 53,973 54,314 54,138
Long-Term Investments
6,768 6,934 6,983 7,593 7,659 10,287 10,784 11,227 11,553 11,759 12,123
Goodwill
25,274 25,291 25,317 25,947 25,962 25,967 28,277 28,420 28,368 28,451 28,340
Intangible Assets
10,703 10,491 10,273 10,710 10,447 10,325 12,094 11,940 11,490 11,327 11,093
Other Noncurrent Operating Assets
2,133 2,329 1,967 2,245 2,196 2,603 2,140 2,392 2,562 2,777 2,582
Total Liabilities & Shareholders' Equity
109,168 110,478 108,928 111,894 112,988 116,533 116,889 119,717 121,938 122,749 125,827
Total Liabilities
70,856 71,939 69,523 71,184 70,691 72,654 75,463 77,097 78,087 78,667 81,785
Total Current Liabilities
41,571 43,337 41,791 44,334 41,813 42,033 40,581 42,698 43,834 40,878 45,309
Short-Term Debt
265 799 1,874 4,475 3,125 2,460 2,014 1,893 2,008 929 1,074
Accounts Payable
5,033 5,983 6,910 5,658 5,760 6,255 6,927 7,131 7,278 6,085 6,209
Other Current Liabilities
36,273 36,555 33,007 34,201 32,763 33,155 31,487 33,674 34,548 33,864 38,026
Total Noncurrent Liabilities
29,285 28,602 27,732 26,850 28,878 30,621 34,882 34,399 34,253 37,789 36,476
Long-Term Debt
24,859 24,045 23,246 21,976 24,561 24,688 29,218 28,110 28,178 31,173 30,768
Noncurrent Deferred & Payable Income Tax Liabilities
1,852 1,779 1,970 2,201 2,037 2,092 2,148 2,121 2,008 2,315 1,786
Other Noncurrent Operating Liabilities
2,574 2,778 2,516 2,673 2,280 3,841 3,516 4,168 4,067 4,301 3,922
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
38,312 38,539 39,405 40,710 42,297 43,879 41,426 42,620 43,851 44,082 44,042
Total Preferred & Common Equity
38,205 38,423 39,306 40,608 42,191 43,775 41,315 42,503 43,722 43,953 43,902
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100
Total Common Equity
38,205 38,423 39,306 40,608 42,191 43,775 41,315 42,503 43,722 43,953 43,902
Common Stock
8,763 8,832 8,870 8,885 9,003 9,107 8,913 8,868 8,933 8,910 8,847
Retained Earnings
31,608 32,103 31,749 33,088 34,575 35,157 33,549 34,546 35,549 35,586 35,796
Accumulated Other Comprehensive Income / (Loss)
-2,166 -2,512 -1,313 -1,365 -1,387 -489 -1,147 -911 -760 -543 -741
Other Equity Adjustments
0.00 0.00 - - - - - - - 0.00 0.00
Noncontrolling Interest
107 116 99 102 106 104 111 117 129 129 140

Annual Metrics And Ratios for Elevance Health

This table displays calculated financial ratios and metrics derived from Elevance Health's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
7.15% 7.21% 6.10% 2.29% 13.15% 16.94% 13.76% 12.95% 9.42% 3.19% 12.62%
EBITDA Growth
4.77% 0.12% -5.07% 18.52% 12.95% 4.40% 22.93% 0.31% 3.59% -0.08% -7.86%
EBIT Growth
4.45% 0.06% -5.55% 16.99% 15.45% 4.83% 24.58% -3.89% 3.48% 3.93% -10.75%
NOPAT Growth
-1.48% -1.84% 68.86% -10.71% 25.32% -4.34% 30.73% -3.19% 3.72% -1.13% 1.93%
Net Income Growth
-0.38% -3.52% 55.59% -2.42% 28.19% -4.89% 34.49% -4.24% 1.75% -0.33% -5.19%
EPS Growth
4.34% -1.81% 55.81% -1.12% 30.16% -2.65% 38.77% -2.69% 3.87% 1.82% -1.83%
Operating Cash Flow Growth
25.01% -22.36% 27.98% -8.55% 58.37% 76.34% -21.74% 0.42% -4.02% -27.95% -26.14%
Free Cash Flow Firm Growth
-25.53% 25.29% -33.61% -61.87% 518.61% 71.50% -54.09% 73.85% -25.32% -89.85% 1,043.95%
Invested Capital Growth
1.67% -3.01% 17.31% 19.54% 0.90% -17.61% 15.04% -2.92% 7.40% 29.16% 2.38%
Revenue Q/Q Growth
1.54% 1.83% 1.09% 0.76% 4.03% 3.76% 3.55% 2.18% 1.61% 1.61% 2.21%
EBITDA Q/Q Growth
-7.08% 4.92% -4.39% 3.18% -2.89% -5.05% 10.16% -2.21% -0.60% -1.31% -3.56%
EBIT Q/Q Growth
-8.57% 5.79% -5.05% 2.72% 9.07% -6.38% 10.85% -3.89% -0.16% -1.23% -4.31%
NOPAT Q/Q Growth
-9.91% 7.36% 38.90% -22.43% 10.68% -6.87% 10.20% -3.47% -0.36% -5.22% 3.71%
Net Income Q/Q Growth
-11.29% 8.22% 28.93% -17.71% 11.87% -7.73% 11.37% -4.04% -0.76% -6.54% 2.41%
EPS Q/Q Growth
-10.33% 7.47% 29.75% -17.74% 12.48% -7.18% 11.63% -4.07% 0.28% -6.55% 2.77%
Operating Cash Flow Q/Q Growth
21.31% -19.03% -27.38% 85.51% 16.63% 30.31% -20.38% -27.53% -15.27% 172.55% -12.66%
Free Cash Flow Firm Q/Q Growth
1.30% -1.08% -62.71% 119.62% 11.12% 10.64% -44.15% -11.38% -24.22% -67.55% 355.29%
Invested Capital Q/Q Growth
-1.82% -0.37% 39.34% -6.08% -6.03% -12.91% 6.60% 10.91% 20.62% 19.05% -0.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
22.79% 21.24% 19.77% 21.94% 19.61% 20.41% 18.16% 17.19% 17.34% 16.68% 14.93%
EBITDA Margin
7.81% 7.29% 6.53% 7.56% 7.55% 6.74% 7.28% 6.47% 6.12% 5.93% 4.85%
Operating Margin
6.66% 6.22% 5.54% 6.33% 6.46% 5.79% 6.34% 5.40% 5.10% 5.03% 4.07%
EBIT Margin
6.66% 6.22% 5.54% 6.33% 6.46% 5.79% 6.34% 5.40% 5.10% 5.14% 4.07%
Profit (Net Income) Margin
3.23% 2.91% 4.27% 4.07% 4.61% 3.75% 4.44% 3.76% 3.50% 3.38% 2.84%
Tax Burden Percent
55.28% 54.23% 96.95% 73.99% 80.32% 73.29% 76.91% 77.47% 77.65% 75.54% 84.37%
Interest Burden Percent
87.80% 86.30% 79.52% 86.90% 88.89% 88.38% 90.92% 89.93% 88.22% 86.96% 82.72%
Effective Tax Rate
44.72% 45.77% 3.05% 26.01% 19.68% 26.71% 23.09% 22.53% 22.35% 24.46% 15.63%
Return on Invested Capital (ROIC)
18.83% 18.61% 29.37% 22.13% 25.35% 26.47% 35.63% 32.72% 33.22% 27.68% 24.73%
ROIC Less NNEP Spread (ROIC-NNEP)
23.19% 23.12% 39.96% 29.18% 32.18% 31.12% 39.54% 36.78% 37.81% 32.28% 32.59%
Return on Net Nonoperating Assets (RNNOA)
-8.01% -8.35% -14.48% -8.50% -9.40% -12.39% -17.90% -16.47% -17.40% -12.90% -11.48%
Return on Equity (ROE)
10.83% 10.26% 14.89% 13.63% 15.95% 14.08% 17.73% 16.24% 15.82% 14.77% 13.25%
Cash Return on Invested Capital (CROIC)
17.17% 21.66% 13.44% 4.32% 24.45% 45.79% 21.64% 35.69% 26.09% 2.23% 22.38%
Operating Return on Assets (OROA)
8.55% 8.32% 7.35% 8.21% 9.04% 8.60% 9.55% 8.44% 8.26% 8.05% 6.81%
Return on Assets (ROA)
4.15% 3.90% 5.67% 5.28% 6.45% 5.57% 6.68% 5.88% 5.66% 5.29% 4.75%
Return on Common Equity (ROCE)
10.83% 10.26% 14.89% 13.63% 15.95% 14.08% 17.71% 16.21% 15.78% 14.74% 13.21%
Return on Equity Simple (ROE_SIMPLE)
11.11% 9.84% 14.50% 13.14% 15.15% 13.77% 17.04% 16.25% 15.24% 14.45% 0.00%
Net Operating Profit after Tax (NOPAT)
2,916 2,862 4,833 4,315 5,408 5,173 6,763 6,547 6,791 6,714 6,844
NOPAT Margin
3.68% 3.37% 5.37% 4.69% 5.19% 4.24% 4.88% 4.18% 3.96% 3.80% 3.44%
Net Nonoperating Expense Percent (NNEP)
-4.36% -4.51% -10.59% -7.05% -6.83% -4.65% -3.91% -4.06% -4.59% -4.60% -7.86%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 10.83% 10.52% 9.24% 9.00%
Cost of Revenue to Revenue
77.21% 78.76% 80.23% 78.06% 80.39% 79.59% 81.84% 82.81% 82.66% 83.32% 85.07%
SG&A Expenses to Revenue
15.84% 14.80% 14.05% 15.22% 12.82% 14.32% 11.48% 11.30% 11.72% 11.33% 10.54%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
16.13% 15.03% 14.24% 15.61% 13.15% 14.62% 11.81% 11.79% 12.24% 11.65% 10.85%
Earnings before Interest and Taxes (EBIT)
5,275 5,278 4,985 5,832 6,733 7,058 8,793 8,451 8,745 9,089 8,112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
6,183 6,190 5,876 6,964 7,866 8,212 10,095 10,126 10,490 10,482 9,658
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.42 1.38 2.03 2.24 2.30 2.32 3.05 3.29 2.78 2.07 1.78
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 28.56 36.65 87.80 77.25 29.42 90.63 17.96
Price to Revenue (P/Rev)
0.41 0.41 0.60 0.69 0.70 0.63 0.79 0.76 0.64 0.48 0.39
Price to Earnings (P/E)
12.79 14.07 13.99 17.06 15.17 16.86 17.85 20.25 18.26 14.31 13.76
Dividend Yield
1.99% 1.97% 1.29% 1.21% 1.11% 1.23% 1.00% 1.02% 1.27% 1.77% 1.95%
Earnings Yield
7.82% 7.11% 7.15% 5.86% 6.59% 5.93% 5.60% 4.94% 5.48% 6.99% 7.27%
Enterprise Value to Invested Capital (EV/IC)
1.62 1.64 2.53 2.67 2.92 3.49 4.64 5.22 4.31 2.61 2.22
Enterprise Value to Revenue (EV/Rev)
0.32 0.29 0.50 0.62 0.60 0.51 0.68 0.66 0.53 0.40 0.31
Enterprise Value to EBITDA (EV/EBITDA)
4.10 4.01 7.66 8.14 7.96 7.49 9.33 10.15 8.69 6.82 6.42
Enterprise Value to EBIT (EV/EBIT)
4.80 4.70 9.03 9.71 9.30 8.72 10.71 12.17 10.43 7.86 7.65
Enterprise Value to NOPAT (EV/NOPAT)
8.68 8.66 9.32 13.13 11.58 11.90 13.92 15.70 13.43 10.64 9.06
Enterprise Value to Operating Cash Flow (EV/OCF)
6.01 7.58 10.76 14.80 10.34 5.76 11.25 12.24 11.31 12.30 14.46
Enterprise Value to Free Cash Flow (EV/FCFF)
9.52 7.44 20.36 67.18 12.01 6.88 22.92 14.40 17.10 131.96 10.02
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.69 0.63 0.75 0.67 0.63 0.60 0.64 0.66 0.64 0.75 0.73
Long-Term Debt to Equity
0.67 0.57 0.66 0.60 0.56 0.58 0.59 0.62 0.59 0.71 0.70
Financial Leverage
-0.35 -0.36 -0.36 -0.29 -0.29 -0.40 -0.45 -0.45 -0.46 -0.40 -0.35
Leverage Ratio
2.61 2.63 2.63 2.58 2.47 2.53 2.65 2.76 2.80 2.79 2.79
Compound Leverage Factor
2.29 2.27 2.09 2.24 2.20 2.23 2.41 2.48 2.47 2.43 2.31
Debt to Total Capital
40.77% 38.52% 42.92% 40.23% 38.76% 37.64% 38.91% 39.89% 38.93% 42.98% 42.13%
Short-Term Debt to Total Capital
1.39% 3.35% 5.49% 4.18% 4.44% 1.31% 3.17% 2.92% 2.90% 2.77% 1.64%
Long-Term Debt to Total Capital
39.39% 35.17% 37.43% 36.06% 34.33% 36.32% 35.74% 36.97% 36.03% 40.21% 40.48%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 0.14% 0.15% 0.15% 0.19%
Common Equity to Total Capital
59.23% 61.48% 57.08% 59.77% 61.24% 62.36% 60.98% 59.96% 60.92% 56.86% 57.68%
Debt to EBITDA
2.57 2.54 3.39 2.76 2.55 2.44 2.28 2.38 2.39 2.98 3.32
Net Debt to EBITDA
-1.20 -1.61 -1.49 -1.05 -1.31 -1.89 -1.57 -1.64 -1.74 -1.36 -1.66
Long-Term Debt to EBITDA
2.48 2.32 2.96 2.47 2.26 2.35 2.10 2.21 2.22 2.79 3.19
Debt to NOPAT
5.44 5.50 4.12 4.45 3.71 3.87 3.41 3.68 3.70 4.65 4.68
Net Debt to NOPAT
-2.55 -3.48 -1.81 -1.69 -1.90 -3.01 -2.34 -2.54 -2.68 -2.12 -2.34
Long-Term Debt to NOPAT
5.26 5.02 3.60 3.99 3.29 3.74 3.13 3.41 3.42 4.35 4.50
Altman Z-Score
2.64 2.69 2.82 3.05 3.24 3.15 3.39 3.46 3.39 3.04 3.09
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.10% 0.21% 0.25% 0.26% 0.30%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.62 1.61 1.55 1.56 1.66 1.55 1.47 1.40 1.44 1.45 1.54
Quick Ratio
1.45 1.47 1.27 1.24 1.32 1.24 1.17 1.09 1.11 1.13 1.16
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,659 3,331 2,212 843 5,217 8,947 4,108 7,141 5,333 541 6,193
Operating Cash Flow to CapEx
698.61% 559.93% 529.08% 316.80% 562.77% 1,046.82% 769.46% 729.08% 621.99% 462.42% 384.41%
Free Cash Flow to Firm to Interest Expense
4.13 4.61 2.17 1.10 6.97 10.91 5.15 8.39 5.18 0.46 4.42
Operating Cash Flow to Interest Expense
6.54 4.52 4.10 5.01 8.10 13.03 10.48 9.87 7.83 4.90 3.06
Operating Cash Flow Less CapEx to Interest Expense
5.61 3.72 3.32 3.43 6.66 11.79 9.12 8.52 6.57 3.84 2.26
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.28 1.34 1.33 1.30 1.40 1.49 1.51 1.56 1.62 1.57 1.67
Accounts Receivable Turnover
11.34 11.01 13.60 19.02 20.41 22.05 20.63 18.73 18.11 16.82 17.68
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
39.94 42.46 43.36 37.52 35.52 36.84 37.46 38.03 39.50 39.24 42.68
Accounts Payable Turnover
5.71 5.86 5.80 5.65 10.09 9.22 10.40 24.52 22.63 21.29 23.78
Days Sales Outstanding (DSO)
32.20 33.16 26.84 19.19 17.89 16.56 17.69 19.49 20.16 21.70 20.65
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
63.91 62.25 62.97 64.55 36.19 39.61 35.10 14.89 16.13 17.14 15.35
Cash Conversion Cycle (CCC)
-31.71 -29.08 -36.12 -45.36 -18.30 -23.05 -17.41 4.60 4.03 4.56 5.30
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
15,613 15,144 17,765 21,237 21,428 17,654 20,309 19,715 21,173 27,346 27,997
Invested Capital Turnover
5.11 5.52 5.47 4.72 4.89 6.24 7.30 7.83 8.38 7.29 7.20
Increase / (Decrease) in Invested Capital
257 -469 2,621 3,472 191 -3,774 2,655 -594 1,458 6,173 651
Enterprise Value (EV)
25,321 24,793 45,018 56,653 62,643 61,540 94,136 102,823 91,195 71,434 62,021
Market Capitalization
32,752 34,749 53,756 63,957 72,943 77,085 109,922 119,351 109,328 85,556 77,906
Book Value per Share
$88.27 $95.28 $103.22 $110.35 $125.13 $133.49 $148.71 $151.75 $167.29 $178.14 $197.45
Tangible Book Value per Share
($10.25) ($1.62) ($4.27) ($3.75) $10.07 $8.46 $5.16 $6.47 $15.82 $4.07 $19.52
Total Capital
38,909 40,827 46,435 47,752 51,813 53,234 59,194 60,444 64,525 72,658 76,072
Total Debt
15,865 15,727 19,932 19,211 20,085 20,035 23,031 24,114 25,120 31,232 32,046
Total Long-Term Debt
15,325 14,359 17,382 17,217 17,787 19,335 21,157 22,349 23,246 29,218 30,797
Net Debt
-7,431 -9,957 -8,738 -7,304 -10,300 -15,545 -15,854 -16,615 -18,232 -14,233 -16,029
Capital Expenditures (CapEx)
603 584 791 1,208 1,077 1,021 1,087 1,152 1,296 1,256 1,116
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8,356 -8,498 -9,308 -7,952 -7,823 -13,735 -14,917 -16,606 -16,257 -14,306 -12,900
Debt-free Net Working Capital (DFNWC)
12,310 14,389 15,457 14,350 17,799 16,998 18,111 17,686 20,112 20,375 23,215
Net Working Capital (NWC)
11,770 13,021 12,907 12,356 15,501 16,298 16,237 15,921 18,238 18,361 21,966
Net Nonoperating Expense (NNE)
356 392 990 565 601 601 614 659 800 743 1,183
Net Nonoperating Obligations (NNO)
-7,431 -9,957 -8,738 -7,304 -10,300 -15,545 -15,854 -16,615 -18,232 -14,080 -16,029
Total Depreciation and Amortization (D&A)
908 912 891 1,132 1,133 1,154 1,302 1,675 1,745 1,393 1,546
Debt-free, Cash-free Net Working Capital to Revenue
-10.56% -10.01% -10.34% -8.63% -7.51% -11.27% -10.76% -10.60% -9.49% -8.09% -6.48%
Debt-free Net Working Capital to Revenue
15.55% 16.96% 17.17% 15.58% 17.08% 13.95% 13.06% 11.29% 11.74% 11.52% 11.66%
Net Working Capital to Revenue
14.87% 15.34% 14.33% 13.42% 14.87% 13.37% 11.71% 10.17% 10.64% 10.38% 11.03%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$9.73 $9.39 $14.70 $14.53 $18.81 $18.23 $25.04 $25.10 $25.38 $25.81 $25.28
Adjusted Weighted Average Basic Shares Outstanding
261.35M 264.38M 255.72M 257.01M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Adjusted Diluted Earnings per Share
$9.38 $9.21 $14.35 $14.19 $18.47 $17.98 $24.73 $24.81 $25.22 $25.68 $25.21
Adjusted Weighted Average Diluted Shares Outstanding
261.35M 264.38M 255.72M 257.01M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
261.35M 264.38M 255.72M 257.01M 252.33M 489.81M 482.61M 237.46M 232.67M 227.35M 220.70M
Normalized Net Operating Profit after Tax (NOPAT)
2,916 2,862 4,833 4,315 5,408 5,173 6,779 6,547 6,791 6,714 6,844
Normalized NOPAT Margin
3.68% 3.37% 5.37% 4.69% 5.19% 4.24% 4.89% 4.18% 3.96% 3.80% 3.44%
Pre Tax Income Margin
5.85% 5.37% 4.40% 5.50% 5.74% 5.12% 5.77% 4.85% 4.50% 4.47% 3.37%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
8.19 7.30 4.88 7.63 9.00 8.61 11.02 9.93 8.49 7.67 5.79
NOPAT to Interest Expense
4.53 3.96 4.73 5.65 7.23 6.31 8.47 7.69 6.59 5.67 4.88
EBIT Less CapEx to Interest Expense
7.26 6.49 4.11 6.05 7.56 7.36 9.66 8.58 7.23 6.61 4.99
NOPAT Less CapEx to Interest Expense
3.59 3.15 3.96 4.07 5.79 5.06 7.11 6.34 5.33 4.61 4.09
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
25.65% 27.69% 18.35% 20.69% 17.02% 20.87% 17.95% 20.87% 23.28% 25.26% 27.01%
Augmented Payout Ratio
84.86% 27.69% 70.34% 65.63% 52.40% 79.92% 48.85% 60.21% 67.95% 73.82% 73.03%

Quarterly Metrics And Ratios for Elevance Health

This table displays calculated financial ratios and metrics derived from Elevance Health's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 220,704,667.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 220,704,667.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 7.99
Growth Metrics
- - - - - - - - - - -
Revenue Growth
7.29% 6.81% 0.96% -0.06% 5.36% 6.55% 14.83% 14.04% 12.33% 9.47% 2.64%
EBITDA Growth
-16.19% -3.61% 6.09% 14.86% -14.41% -20.19% -0.59% -16.33% 7.09% -26.56% -14.20%
EBIT Growth
-18.25% -1.10% 11.64% 20.87% -12.55% -24.92% -1.97% -19.38% 5.02% -38.58% -15.28%
NOPAT Growth
-14.47% -2.17% 11.64% 13.50% -16.41% -38.36% 0.03% -14.08% 18.02% 128.86% -17.12%
Net Income Growth
-18.65% -5.25% 12.23% 23.98% -22.46% -50.30% -2.89% -24.21% 17.76% 32.20% -19.41%
EPS Growth
-17.67% 1.94% 15.54% 26.44% -20.00% -48.91% 0.21% -21.62% 22.02% 36.17% -16.75%
Operating Cash Flow Growth
-46.93% -95.72% -69.42% -77.08% 2.45% 123.76% -48.58% 359.51% -57.60% -88.10% 325.96%
Free Cash Flow Firm Growth
-43.13% -124.77% -181.89% -273.56% -341.03% -1,241.86% 30.09% 114.00% 9.70% 114.91% 255.18%
Invested Capital Growth
-1.25% 7.40% 29.44% 44.14% 30.85% 29.16% 19.07% 4.51% 22.81% 2.38% -3.81%
Revenue Q/Q Growth
-1.88% -0.47% -0.16% 2.51% 3.43% 0.66% 7.59% 1.81% 1.88% -1.90% 0.87%
EBITDA Q/Q Growth
-25.39% -28.00% 109.92% 1.87% -44.40% -32.87% 161.46% -14.26% -28.84% -53.96% 205.47%
EBIT Q/Q Growth
-29.20% -34.13% 154.29% 1.94% -48.78% -43.45% 232.03% -16.17% -33.27% -66.93% 358.00%
NOPAT Q/Q Growth
-26.81% -30.43% 134.39% -4.89% -46.10% -48.71% 280.42% -18.31% -25.96% -0.53% 37.77%
Net Income Q/Q Growth
-29.96% -36.08% 170.64% 2.31% -56.19% -59.03% 428.81% -20.15% -31.94% -54.00% 222.34%
EPS Q/Q Growth
-30.04% -32.48% 160.60% 2.71% -55.74% -56.88% 411.17% -19.67% -31.09% -51.88% 212.50%
Operating Cash Flow Q/Q Growth
34.00% -213.70% 166.58% -77.40% 498.88% -73.63% 44.05% 101.97% -44.74% -92.60% 5,057.14%
Free Cash Flow Firm Q/Q Growth
-48.20% -123.88% -591.10% -103.08% 28.07% -32.92% 64.00% 140.67% -563.97% 121.95% 274.63%
Invested Capital Q/Q Growth
-4.51% 20.62% 10.05% 13.72% -13.31% 19.05% 1.46% -0.19% 1.87% -0.75% -4.68%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
17.73% 26.48% 19.27% 7.30% 4.06% 35.79% 17.58% 15.62% 14.18% 12.38% 18.14%
EBITDA Margin
5.46% 3.95% 8.30% 8.25% 4.43% 2.96% 7.19% 6.05% 4.23% 1.98% 6.01%
Operating Margin
4.46% 2.95% 7.53% 6.93% 3.79% 2.08% 6.42% 5.29% 3.46% 1.17% 5.30%
EBIT Margin
4.46% 2.95% 7.53% 7.48% 3.71% 2.08% 6.42% 5.29% 3.46% 1.17% 5.30%
Profit (Net Income) Margin
3.03% 1.95% 5.28% 5.27% 2.23% 0.91% 4.47% 3.50% 2.34% 1.10% 3.51%
Tax Burden Percent
78.60% 83.02% 76.52% 77.06% 73.42% 68.15% 78.08% 76.09% 84.42% 253.95% 76.39%
Interest Burden Percent
86.46% 79.44% 91.73% 91.43% 82.07% 64.06% 89.05% 87.05% 80.02% 37.01% 86.58%
Effective Tax Rate
21.40% 16.98% 23.48% 22.94% 26.58% 31.85% 21.92% 23.91% 15.58% -153.95% 23.61%
Return on Invested Capital (ROIC)
33.50% 20.56% 47.89% 40.88% 23.91% 10.34% 35.99% 28.11% 22.27% 21.34% 29.83%
ROIC Less NNEP Spread (ROIC-NNEP)
34.53% 21.79% 48.99% 41.05% 25.10% 11.77% 37.66% 29.74% 23.88% 27.52% 31.52%
Return on Net Nonoperating Assets (RNNOA)
-18.17% -10.03% -23.10% -18.20% -12.76% -4.71% -14.59% -11.03% -9.99% -9.70% -11.72%
Return on Equity (ROE)
15.32% 10.53% 24.78% 22.69% 11.15% 5.63% 21.40% 17.08% 12.28% 11.65% 18.11%
Cash Return on Invested Capital (CROIC)
39.84% 26.09% 8.46% -3.53% 8.23% 2.23% 8.90% 19.14% 5.32% 22.38% 27.50%
Operating Return on Assets (OROA)
7.05% 4.78% 11.70% 11.57% 5.68% 3.26% 10.16% 8.52% 5.64% 1.95% 8.66%
Return on Assets (ROA)
4.79% 3.15% 8.21% 8.15% 3.42% 1.42% 7.06% 5.65% 3.81% 1.83% 5.73%
Return on Common Equity (ROCE)
15.29% 10.50% 24.72% 22.63% 11.12% 5.62% 21.35% 17.04% 12.25% 11.61% 18.05%
Return on Equity Simple (ROE_SIMPLE)
15.71% 0.00% 15.36% 15.84% 14.60% 0.00% 13.90% 12.23% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,504 1,046 2,452 2,332 1,257 645 2,453 2,003 1,483 1,475 2,033
NOPAT Margin
3.51% 2.45% 5.76% 5.34% 2.78% 1.42% 5.02% 4.03% 2.93% 2.97% 4.05%
Net Nonoperating Expense Percent (NNEP)
-1.04% -1.23% -1.10% -0.17% -1.19% -1.43% -1.66% -1.62% -1.61% -6.17% -1.69%
Return On Investment Capital (ROIC_SIMPLE)
- 1.62% - - - 0.89% 3.38% 2.71% 1.95% 1.94% 2.68%
Cost of Revenue to Revenue
82.28% 73.52% 80.73% 92.70% 95.94% 64.21% 82.42% 84.38% 85.82% 87.62% 81.86%
SG&A Expenses to Revenue
12.77% 0.00% 11.48% 0.00% 0.00% 0.00% 10.84% 10.04% 10.40% 10.89% 12.61%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
13.26% 23.53% 11.75% 0.37% 0.27% 33.71% 11.16% 10.33% 10.72% 11.21% 12.84%
Earnings before Interest and Taxes (EBIT)
1,913 1,260 3,204 3,266 1,673 946 3,141 2,633 1,757 581 2,661
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,339 1,684 3,535 3,601 2,002 1,344 3,514 3,013 2,144 987 3,015
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.64 2.78 3.00 2.98 2.75 2.07 2.33 2.01 1.66 1.78 1.47
Price to Tangible Book Value (P/TBV)
38.37 29.42 30.84 21.78 16.11 90.63 46.15 22.74 17.43 17.96 14.46
Price to Revenue (P/Rev)
0.60 0.64 0.71 0.73 0.69 0.48 0.54 0.46 0.37 0.39 0.32
Price to Earnings (P/E)
16.90 18.26 19.51 18.82 18.79 14.31 16.71 16.40 13.15 13.76 12.32
Dividend Yield
1.33% 1.27% 1.17% 1.15% 1.23% 1.77% 1.52% 1.72% 2.09% 1.95% 2.34%
Earnings Yield
5.92% 5.48% 5.12% 5.31% 5.32% 6.99% 5.98% 6.10% 7.60% 7.27% 8.11%
Enterprise Value to Invested Capital (EV/IC)
4.58 4.31 4.49 4.15 4.34 2.61 3.03 2.59 2.02 2.22 1.78
Enterprise Value to Revenue (EV/Rev)
0.48 0.53 0.61 0.64 0.57 0.40 0.46 0.38 0.29 0.31 0.24
Enterprise Value to EBITDA (EV/EBITDA)
7.63 8.69 9.78 10.08 9.38 6.82 8.20 7.25 5.69 6.42 5.19
Enterprise Value to EBIT (EV/EBIT)
9.19 10.43 11.51 11.71 10.83 7.86 9.53 8.52 6.73 7.65 6.22
Enterprise Value to NOPAT (EV/NOPAT)
11.81 13.43 14.83 15.03 14.06 10.64 12.53 11.26 8.64 9.06 7.39
Enterprise Value to Operating Cash Flow (EV/OCF)
8.46 11.31 29.28 53.26 46.74 12.30 17.36 11.13 11.61 14.46 6.25
Enterprise Value to Free Cash Flow (EV/FCFF)
11.44 17.10 59.82 0.00 59.71 131.96 37.03 13.85 41.92 10.02 6.35
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.64 0.64 0.65 0.65 0.62 0.75 0.70 0.69 0.73 0.73 0.72
Long-Term Debt to Equity
0.62 0.59 0.54 0.58 0.56 0.71 0.66 0.64 0.71 0.70 0.70
Financial Leverage
-0.53 -0.46 -0.47 -0.44 -0.51 -0.40 -0.39 -0.37 -0.42 -0.35 -0.37
Leverage Ratio
2.86 2.80 2.83 2.76 2.75 2.79 2.78 2.73 2.72 2.79 2.83
Compound Leverage Factor
2.48 2.22 2.59 2.52 2.26 1.79 2.48 2.37 2.18 1.03 2.45
Debt to Total Capital
39.20% 38.93% 39.38% 39.56% 38.22% 42.98% 41.31% 40.77% 42.14% 42.13% 41.96%
Short-Term Debt to Total Capital
1.26% 2.90% 6.66% 4.47% 3.46% 2.77% 2.61% 2.71% 1.22% 1.64% 1.42%
Long-Term Debt to Total Capital
37.94% 36.03% 32.72% 35.10% 34.76% 40.21% 38.71% 38.06% 40.92% 40.48% 40.55%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.13%
Noncontrolling Interests to Total Capital
0.18% 0.15% 0.15% 0.15% 0.15% 0.15% 0.16% 0.17% 0.17% 0.19% 0.18%
Common Equity to Total Capital
60.62% 60.92% 60.46% 60.29% 61.63% 56.86% 58.53% 59.05% 57.69% 57.68% 57.85%
Debt to EBITDA
2.35 2.39 2.47 2.54 2.56 2.98 2.92 3.05 3.21 3.32 3.48
Net Debt to EBITDA
-1.99 -1.74 -1.63 -1.46 -1.98 -1.36 -1.45 -1.63 -1.58 -1.66 -1.89
Long-Term Debt to EBITDA
2.28 2.22 2.06 2.25 2.32 2.79 2.74 2.84 3.11 3.19 3.36
Debt to NOPAT
3.65 3.70 3.75 3.78 3.83 4.65 4.47 4.73 4.86 4.68 4.95
Net Debt to NOPAT
-3.08 -2.68 -2.47 -2.18 -2.97 -2.12 -2.22 -2.53 -2.41 -2.34 -2.70
Long-Term Debt to NOPAT
3.53 3.42 3.12 3.35 3.49 4.35 4.19 4.42 4.72 4.50 4.79
Altman Z-Score
3.03 3.16 3.25 3.33 3.17 2.81 2.97 2.90 2.82 2.88 2.74
Noncontrolling Interest Sharing Ratio
0.23% 0.25% 0.26% 0.26% 0.27% 0.26% 0.26% 0.27% 0.26% 0.30% 0.30%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.41 1.44 1.37 1.49 1.50 1.45 1.43 1.44 1.56 1.54 1.48
Quick Ratio
1.11 1.11 1.03 1.13 1.17 1.13 1.07 1.08 1.20 1.16 1.07
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1,726 -412 -2,847 -5,782 -4,159 -5,528 -1,990 809 -3,756 824 3,089
Operating Cash Flow to CapEx
819.12% -911.35% 708.96% 138.39% 806.33% 219.25% 518.88% 769.29% 315.28% 28.67% 1,843.40%
Free Cash Flow to Firm to Interest Expense
6.66 -1.59 -10.74 -20.65 -13.86 -16.26 -5.79 2.37 -10.70 2.25 8.65
Operating Cash Flow to Interest Expense
10.09 -11.47 7.46 1.60 8.92 2.08 2.96 6.02 3.23 0.23 12.13
Operating Cash Flow Less CapEx to Interest Expense
8.86 -12.73 6.41 0.44 7.82 1.13 2.39 5.24 2.21 -0.57 11.48
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.58 1.62 1.55 1.55 1.53 1.57 1.58 1.61 1.63 1.67 1.63
Accounts Receivable Turnover
20.35 18.11 19.27 16.94 17.20 16.82 17.29 15.88 16.23 17.68 17.36
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
39.93 39.50 38.73 38.17 39.76 39.24 40.39 41.64 42.53 42.68 43.22
Accounts Payable Turnover
11.01 22.63 26.92 26.21 24.43 21.29 23.96 24.52 25.94 23.78 25.51
Days Sales Outstanding (DSO)
17.94 20.16 18.94 21.54 21.23 21.70 21.11 22.99 22.49 20.65 21.02
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
33.16 16.13 13.56 13.93 14.94 17.14 15.23 14.89 14.07 15.35 14.31
Cash Conversion Cycle (CCC)
-15.23 4.03 5.38 7.62 6.29 4.56 5.88 8.10 8.42 5.30 6.72
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
17,554 21,173 23,301 26,498 22,970 27,346 27,744 27,692 28,209 27,997 26,688
Invested Capital Turnover
9.55 8.38 8.32 7.65 8.59 7.29 7.18 6.98 7.61 7.20 7.36
Increase / (Decrease) in Invested Capital
-222 1,458 5,299 8,114 5,416 6,173 4,443 1,194 5,239 651 -1,056
Enterprise Value (EV)
80,479 91,195 104,529 110,080 99,613 71,434 84,130 71,850 57,016 62,021 47,497
Market Capitalization
101,348 109,328 121,836 125,938 120,581 85,556 98,889 87,880 72,760 77,906 64,611
Book Value per Share
$163.05 $167.29 $174.72 $181.53 $188.78 $178.14 $186.95 $193.52 $195.19 $197.45 $198.92
Tangible Book Value per Share
$11.21 $15.82 $17.00 $24.88 $32.27 $4.07 $9.43 $17.10 $18.54 $19.52 $20.25
Total Capital
63,383 64,525 67,161 69,983 71,027 72,658 72,623 74,037 76,184 76,072 75,884
Total Debt
24,844 25,120 26,451 27,686 27,148 31,232 30,003 30,186 32,102 32,046 31,842
Total Long-Term Debt
24,045 23,246 21,976 24,561 24,688 29,218 28,110 28,178 31,173 30,797 30,768
Net Debt
-20,985 -18,232 -17,409 -15,964 -21,072 -14,233 -14,876 -16,159 -15,873 -16,029 -17,354
Capital Expenditures (CapEx)
319 326 279 323 332 322 196 267 360 293 235
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-20,248 -16,257 -15,178 -12,405 -14,660 -14,306 -13,336 -13,294 -12,387 -12,900 -14,276
Debt-free Net Working Capital (DFNWC)
18,647 20,112 21,089 23,586 23,273 20,375 20,316 21,498 23,829 23,215 22,797
Net Working Capital (NWC)
17,848 18,238 16,614 20,461 20,813 18,361 18,423 19,490 22,900 21,966 21,723
Net Nonoperating Expense (NNE)
204 215 203 31 249 232 269 259 296 929 273
Net Nonoperating Obligations (NNO)
-20,985 -18,232 -17,409 -15,799 -20,909 -14,080 -14,876 -16,159 -15,873 -16,029 -17,354
Total Depreciation and Amortization (D&A)
426 424 331 335 329 398 373 380 387 406 354
Debt-free, Cash-free Net Working Capital to Revenue
-12.01% -9.49% -8.84% -7.22% -8.42% -8.09% -7.28% -7.02% -6.36% -6.48% -7.12%
Debt-free Net Working Capital to Revenue
11.06% 11.74% 12.28% 13.74% 13.37% 11.52% 11.09% 11.36% 12.23% 11.66% 11.37%
Net Working Capital to Revenue
10.58% 10.64% 9.67% 11.92% 11.96% 10.38% 10.06% 10.30% 11.75% 11.03% 10.84%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$5.48 $3.70 $9.65 $9.91 $4.38 $1.87 $9.64 $7.74 $5.32 $2.58 $8.03
Adjusted Weighted Average Basic Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Adjusted Diluted Earnings per Share
$5.45 $3.68 $9.59 $9.85 $4.36 $1.88 $9.61 $7.72 $5.32 $2.56 $8.00
Adjusted Weighted Average Diluted Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
234.96M 232.67M 232.42M 231.89M 231.92M 227.35M 225.93M 225.18M 222.24M 220.70M 217.16M
Normalized Net Operating Profit after Tax (NOPAT)
1,504 1,046 2,452 2,332 1,257 645 2,453 2,003 1,483 407 2,033
Normalized NOPAT Margin
3.51% 2.45% 5.76% 5.34% 2.78% 1.42% 5.02% 4.03% 2.93% 0.82% 4.05%
Pre Tax Income Margin
3.86% 2.35% 6.90% 6.84% 3.04% 1.33% 5.72% 4.60% 2.77% 0.43% 4.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
7.39 4.86 12.09 11.66 5.58 2.78 9.13 7.72 5.01 1.59 7.45
NOPAT to Interest Expense
5.81 4.04 9.25 8.33 4.19 1.90 7.13 5.88 4.23 4.03 5.69
EBIT Less CapEx to Interest Expense
6.15 3.61 11.04 10.51 4.47 1.84 8.56 6.94 3.98 0.79 6.80
NOPAT Less CapEx to Interest Expense
4.57 2.78 8.20 7.17 3.08 0.95 6.56 5.09 3.20 3.23 5.04
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
22.43% 23.28% 22.82% 21.72% 23.18% 25.26% 25.65% 28.45% 27.59% 27.01% 29.01%
Augmented Payout Ratio
60.79% 67.95% 64.83% 58.19% 54.75% 73.82% 80.07% 86.95% 98.95% 73.03% 83.41%

Financials Breakdown Chart

Key Financial Trends

Note: the provided JSON data corresponds to Elevance Health, Inc. (ELV), not Anthem, Inc. (ANTM). Below is a concise, four-year trend snapshot based on the ELV statements in the data you shared.

Over the period, Elevance Health shows a generally larger revenue base with improving earnings, though operating margins show some compression in the most recent quarter. The balance sheet remains asset-rich with a substantial equity base, while cash flow shows a mix of favorable operating cash flow in earlier 2025 quarters and a noticeable pullback in Q4 2025. Leverage remains elevated, driven by long-term debt, but the company maintains solid liquidity as seen in cash and equivalents.

  • Operating revenue rose to about $49.75 billion in Q4 2025 from about $45.52 billion in Q4 2024, indicating continued top-line expansion across the four-year view.
  • Earnings per share rose to 2.58 (basic) and 2.56 (diluted) in Q4 2025, from 1.87 (basic) in Q4 2024, signaling improved profitability per share year over year.
  • Net income attributable to common shareholders climbed to $547 million in Q4 2025 versus about $413 million in Q3 2024, reflecting stronger annualized earnings power in the latest period.
  • Total assets remained robust, around $122.75 billion by late 2025, up from about $110–117 billion levels in earlier 2024–2023 periods, indicating a growing asset base to support operations.
  • Gross profit in Q4 2025 was $6.16 billion, down from $7.77 billion in Q3 2025, suggesting margin compression on a quarterly basis even as revenues grew.
  • Operating margin weakened in Q4 2025 (Total Operating Income of about $581 million on ~$49.75 billion in revenue) versus higher quarterly operating profit earlier in 2025, indicating tighter cost control or mix shifts.
  • Operating cash flow in 2025 quarters was variable: notably strong in Q2 2025 (~$2.05B) and Q3 2025 (~$1.14B), but much weaker in Q4 2025 (~$84 million), signaling volatility in cash generation from operations.
  • Total liabilities remained substantial (~$78.7 billion by Q3 2025) with long-term debt around $31.2 billion, implying persistent leverage pressures to monitor going forward.
  • Investing cash flow was cash outflow-intensive in late 2025, with net cash used for continuing investing activities (~$0.46 billion in Q4 2025), contributing to weaker overall cash movement that quarter.
  • Gross margin compression combined with a substantial debt load could challenge margin recovery if underlying cost dynamics remain elevated or if revenue growth slows in future periods.
05/18/26 06:50 AM ETAI Generated. May Contain Errors.

Elevance Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Elevance Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Elevance Health's net income appears to be on an upward trend, with a most recent value of $5.66 billion in 2025, rising from $2.56 billion in 2015. The previous period was $5.97 billion in 2024. Check out Elevance Health's forecast to explore projected trends and price targets.

Elevance Health's total operating income in 2025 was $8.11 billion, based on the following breakdown:
  • Total Gross Profit: $29.72 billion
  • Total Operating Expenses: $21.61 billion

Over the last 10 years, Elevance Health's total revenue changed from $79.16 billion in 2015 to $199.13 billion in 2025, a change of 151.6%.

Elevance Health's total liabilities were at $77.47 billion at the end of 2025, a 2.7% increase from 2024, and a 100.3% increase since 2015.

In the past 10 years, Elevance Health's cash and equivalents has ranged from $2.11 billion in 2015 to $9.49 billion in 2025, and is currently $9.49 billion as of their latest financial filing in 2025.

Over the last 10 years, Elevance Health's book value per share changed from 88.27 in 2015 to 197.45 in 2025, a change of 123.7%.



Financial statements for NYSE:ELV last updated on 4/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners